Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune-mediated destruction of pancreatic B cells. While autoreactive T cells are key ...

In a discussion hosted by Dr. Zachary Roberts, Executive Vice President of R&D and Chief Medical Officer at Allogene Therapeutics, leading rheumatologists Dr. Chris Wincup of King’s College Hospital ...

Researchers from Tr1x Inc. presented the development of TRX-319, a novel allogeneic regulatory T-cell therapy designed for the treatment of autoimmune disorders.

Immune checkpoint pathways regulate T cell function and play pivotal roles in the treatment of both cancer and autoimmune diseases. One key component of these pathways is Lymphocyte Activation Gene 3 ...

Autoimmune diseases share the same core pathology despite their differing clinical manifestations: dysregulated B and T cell activity. B cells contribute to disease progression by secreting ...

Chimeric antigen receptor T (CAR-T) cell therapy has emerged as a transformative approach in modern medicine, demonstrating remarkable efficacy in targeting pathogenic B-cell lineages with ...